SenesTech receives Nasdaq non-compliance notice for audit committee independence; cure period granted

SenesTech, Inc.

Director Delphine François Chiavarini left board and audit committee at 2024 annual meeting, leaving audit committee below three independent members.
Nasdaq granted cure period until earlier of next annual meeting or July 11, 2025; if annual meeting before Jan 7, 2025, compliance due by Jan 7, 2025.
Company intends to identify and appoint a new independent director to regain compliance during cure period.
No immediate effect on common stock listing on Nasdaq Capital Market, but compliance cannot be assured.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.